AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06518057 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Craniospinal Irradiation
Description: Undergo proton CSI
Study NCT06518057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06518057 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo photon VMAT CSI
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hippocampal-Avoidance Craniospinal Irradiation
Description: Undergo HA
Study NCT05164172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for infusion
Study NCT04739059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
Study NCT06398470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NeuroSAFE procedure
Description: Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.
Study NCT06398470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LaserSAFE procedure
Description: The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
Study NCT06601933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions.
Study NCT06601933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions.
Study NCT05731492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administered orally.
Study NCT06625008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed model
Description: The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
Study NCT03861676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal brachytherapy with PSMA PET imaging
Description: Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
Study NCT03861676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)DCFPyL
Description: 18F-DCFPyl PET/CT scan
Study NCT05340582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Injection
Description: Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
Study NCT05340582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
Study NCT05340582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
Study NCT05340582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9% injection
Description: Placebo- IV q6h for 3 days
Study NCT06713577 — intervention group
Intervention type: DEVICE
Intervention: CEREC Cercon 4D
Description: One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations.
Study NCT06732531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH011
Description: BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
Study NCT06733441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-254
Description: TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
Study NCT06733441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-254
Description: TLN-254 will be administered orally at a specified dose on specified days.
Study NCT06753097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous finger-cuff arterial pressure monitoring
Description: Arterial pressure will be monitored using continuous non-invasive finger-cuff arterial pressure monitoring.
Study NCT06765213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Open Ended Oral Food Challenge
Description: Allergens determined to be sensitized will be brought in for an oral challenge to that food.
Study NCT06765213 — intervention group
Intervention type: OTHER
Intervention: Early Introduction
Description: Infants that are not sensitized will have the food introduced to their diet at regular intervals.
Study NCT06761768 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Corticosteroids Triamcinolone Acetonide
Description: ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
Study NCT06761768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids Triamcinolone Acetonide
Description: ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
Study NCT06761768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave
Description: a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session)
Study NCT06761768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: extracorporeal shockwave(minimum intensity)
Description: a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session)
Study NCT06762301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual education and counseling
Description: After the initial evaluation, pregnant women who will be included in the study group will be given an appointment for 1 week later, they will be asked to come with their partners and couples will be given sexual education and counseling in line with the PLISSIT model. After the initial evaluation, couples will be interviewed in the 1st, 2nd and 3rd trimesters, their sexuality since the previous evaluation according to the PLISSIT model, their problems, if any, will be discussed and short counseling will be given if necessary. In the first 4 weeks after delivery, couples in the study group will receive sexual education and counseling for the postpartum period in line with the PLISSIT model. They will be interviewed at the 3rd and 6th month after delivery and their postpartum sexuality and problems, if any, will be discussed and the sexual functions of the couples for the last 4 weeks will be evaluated.
Study NCT06762301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical care
Description: Control Group
Study NCT06765681 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of both VTE and sepsis
Description: Both diagnoses need to present during ICU stay for case inclusion into this retrospective study
Study NCT06766591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab combined with chemotherapy
Description: Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
Study NCT06766474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
Study NCT06765629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group
Description: After obtaining informed consent from the subjects, the researchers screen the subjects based on the inclusion and exclusion criteria. The wearable non-invasive percutaneous tibial nerve stimulator is placed on the area where the tibial nerve runs at the medial malleolus of the subjects. Once the wearable stimulator is properly fitted, stimulation parameter programming and treatment record management are conducted through the programming software running on the mobile phone.
Study NCT06767332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye movement desensitization and reprocessing (EMDR)
Description: EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxiety disorders (e.g. fear of illness and specific phobia) (Logie \& de Jongh, 2014) and somatic complaints such as post-operative pain, medically unexplained symptoms and seizure-related post-traumatic stress (Dautovic, de Roos, van Rood, Dommerholt, \& Rodenburg, 2016; van Rood \& de Roos, 2009; Maroufi, Zamani, Izadikhah, Marofi, \& O'Connor, 2016).~With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology including physical symptoms and fear of future catastrophes (Balkom van et al., 2013).
Study NCT06767124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Supplement
Description: Commercially available ketone ester drink
Study NCT06767124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink containing sunflower oil.
Study NCT06765902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: A subcutaneous injection of an IL-15 superagonist.
Study NCT06765902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETBX-071
Description: A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.
Study NCT06765902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-CENK
Description: An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
Study NCT06766721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (USG)
Description: The intervention involves the use of a portable ultrasound (USG) device to assess costochondral joint separation in patients with blunt thoracic trauma. The ultrasound examination will focus on detecting disruptions in the connection between the ribs and cartilage, providing a non-invasive, radiation-free diagnostic method. A 12-MHz linear transducer will be used to scan the rib area for fractures or separations. The findings will be compared to those of computed tomography (CT), considered the gold standard. This intervention is designed to evaluate the accuracy, sensitivity, and specificity of ultrasound as a diagnostic tool in this context.
Study NCT06766032 — intervention group
Intervention type: DEVICE
Intervention: CELL-Saver
Description: The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
Study NCT06766032 — intervention group
Intervention type: DEVICE
Intervention: SAME
Description: The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
Study NCT06766227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEndSmokin App
Description: Mobile Health App that includes educational material and psychological programs based on CBT.
Study NCT06766227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Session
Description: It will include lectures and distribution of educational material about smoking health risks and strategies to quit.
Study NCT06765486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb resistance training
Description: Exercise intervention with leg extensions on the dominant quadriceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
Study NCT06765486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb resistance training
Description: Exercise intervention with brachial biceps curl on the dominant brachial biceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
Study NCT06769295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
Study NCT06769464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: odor
Description: present odor
Study NCT06769776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Drain i.e. Omission of abdominal drain placement
Description: Omission of abdominal drain placement in intervention arm. The No-drain arm will be compared to drain arm
Study NCT06769867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PS-3D-DSA
Description: undergo a PS-3D-DSA scan
Study NCT06769867 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: classic 3D-DSA
Description: undergo a classic 3D-DSA scan
Study NCT06768073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham (No Treatment)
Description: The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
Study NCT06768073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin 25 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin 1 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin 1 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone 750 mg
Description: metyrapone 750mg capsules, which will be administered in 2 doses
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone 750 mg
Description: metyrapone 750mg capsules, which will be administered in 2 doses
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: inactive placebo
Study NCT06768944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo
Study NCT06768281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Headache Impact Test-6 (HIT-6)
Description: Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
Study NCT06768281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
Study NCT06768281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Score (VAS)
Description: Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.
Study NCT06768281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masseter muscle injection
Description: 1 ml of insulin needle with a 27-gauge ½ inch 13 mm needle tip will be injected into up to 4 trigger points in the taut bands that cause the most pain in the masseter muscle. Injections were done at most 3 times. As the control group, the first group was injected with isotonic saline; the second group was injected with 2% lidocaine without vasoconstrictor; the third group with ozone gas; and the fourth group with ozonated isotonic saline.